Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

631 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group.
Ueda T, Miyawaki S, Asou N, Kuraishi Y, Hiraoka A, Kuriyama K, Minami S, Ohshima T, Ino T, Tamura J, Kanamaru A, Nishikawa K, Tanimoto M, Oh H, Saito K, Nagata K, Naoe T, Yamada O, Urasaki Y, Sakura T, Ohno R. Ueda T, et al. Among authors: ohno r. Int J Hematol. 1998 Oct;68(3):279-89. doi: 10.1016/s0925-5710(98)00075-9. Int J Hematol. 1998. PMID: 9846012 Clinical Trial.
Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.
Morita Y, Kanamaru A, Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, Kuriyama K, Kobayashi T, Imoto S, Ohnishi K, Naoe T, Ohno R. Morita Y, et al. Among authors: ohno r. Int J Hematol. 2010 Jan;91(1):97-103. doi: 10.1007/s12185-009-0473-4. Epub 2010 Jan 5. Int J Hematol. 2010. PMID: 20047095 Clinical Trial.
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.
Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Among authors: ohno r. Int J Hematol. 2010 Mar;91(2):276-83. doi: 10.1007/s12185-009-0480-5. Int J Hematol. 2010. PMID: 20054669 Clinical Trial.
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.
Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R, Ohno R. Wakita A, et al. Among authors: ohno r. Int J Hematol. 2012 Jul;96(1):84-93. doi: 10.1007/s12185-012-1105-y. Epub 2012 May 26. Int J Hematol. 2012. PMID: 22639053 Clinical Trial.
Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group.
Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N, Tomonaga M, Tsubaki K, Takahashi I, Kodera Y, et al. Ohno R, et al. Cancer. 1993 Jun 15;71(12):3888-95. doi: 10.1002/1097-0142(19930615)71:12<3888::aid-cncr2820711216>3.0.co;2-g. Cancer. 1993. PMID: 8508355 Clinical Trial.
Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Ohno R, et al. Kobayashi T, et al. Among authors: ohno r. J Clin Oncol. 1996 Jan;14(1):204-13. doi: 10.1200/JCO.1996.14.1.204. J Clin Oncol. 1996. PMID: 8558199 Clinical Trial.
Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. The Japan Adult Leukemia Study Group.
Takeshita A, Sakamaki H, Miyawaki S, Kobayashi T, Kuriyama K, Yamada O, Oh H, Takenaka T, Asou N, Ohno R. Takeshita A, et al. Among authors: ohno r. Cancer. 1995 Aug 15;76(4):602-8. doi: 10.1002/1097-0142(19950815)76:4<602::aid-cncr2820760410>3.0.co;2-l. Cancer. 1995. PMID: 8625153
631 results